Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
Earnings Data
Report Date
Feb 24, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.28Last Year’s EPS
-0.11Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth, successful strategic initiatives, and international expansion. However, increased operating expenses and onetime financial impacts were noted as challenges. Overall, the highlights of growth and strategic progress outweigh the lowlights.Company Guidance
Record Revenue Growth
Total revenue for Q3 2025 grew 69% year-over-year to $87.3 million, with U.S. net product revenue increasing 31% year-over-year to $40.7 million.
Commercial Strategy Success
Esperion achieved nearly double-digit sequential quarterly prescription growth. Their strategic marketing initiatives, such as the 'Can’t take a statin? Make NEXLIZET happen!' campaign, have significantly increased brand awareness and prescriber engagement.
Strategic Partnerships and Approvals
Esperion finalized agreements with 4 generic manufacturers, ensuring no market entry of generic versions of NEXLETOL and NEXLIZET before April 2040. Additionally, bempedoic acid was included in the ESC/EAS guidelines, with U.S. guidelines expected to follow in early 2026.
International Expansion
Partnerships with Daiichi Sankyo Europe and Otsuka Pharmaceutical have shown strong growth, with significant market shares in Europe and upcoming launch in Japan. Royalty revenue from DSE increased 21% sequentially to $16.4 million.
Pipeline Advancements
Nomination of ESP-2001 as a preclinical development candidate for primary sclerosing cholangitis, with plans to initiate first-in-human clinical studies in 2026.
ESPR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ESPR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $2.94 | $2.50 | -14.97% |
Aug 11, 2025 | $1.87 | $1.84 | -1.60% |
May 06, 2025 | $1.05 | $0.98 | -6.67% |
Mar 04, 2025 | $1.58 | $1.77 | +12.03% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Esperion (ESPR) report earnings?
Esperion (ESPR) is schdueled to report earning on Feb 24, 2026, TBA (Confirmed).
What is Esperion (ESPR) earnings time?
Esperion (ESPR) earnings time is at Feb 24, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ESPR EPS forecast?
ESPR EPS forecast for the fiscal quarter 2025 (Q4) is 0.28.